Scalper1 News
Swiss pharma giant Novartis (NVS) was up nearly 4% to a new high above 93 in early trading on the stock market today after it released positive clinical-trial data on its heart-failure drug over the weekend. At least one analyst says that the drug could top $6 billion in annual sales. At the European Society of Cardiology Congress in Barcelona, Novartis presented results of a study of patients with heart failure with reduced ejection fraction, Scalper1 News
Scalper1 News